Search

Your search keyword '"Hoshino, Tomoaki"' showing total 814 results

Search Constraints

Start Over You searched for: Author "Hoshino, Tomoaki" Remove constraint Author: "Hoshino, Tomoaki"
814 results on '"Hoshino, Tomoaki"'

Search Results

3. A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib

9. Sensitivity of transbronchial lung cryobiopsy in the diagnosis of different interstitial lung diseases

11. Examination of prognostic factors in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.

12. Altered Functional Connectivity during Mild Transient Respiratory Impairment Induced by a Resistive Load

17. IL-18 receptor-α signalling pathway contributes to autoantibody-induced arthritis via neutrophil recruitment and mast cell activation.

20. A Case in which Eosinophilic Meningoencephalitis Occurred during Oral Corticosteroid Tapering and after Switching from Anti-IL-5 to Anti-IgE Treatment

24. Periostin Is a Biomarker of Rheumatoid Arthritis-Associated Interstitial Lung Disease

25. Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report

32. Five-year follow up analysis of Japanese ILD registry

34. Combination of Prednisolone and Calcineurin Inhibitors Prevents Lung Function Decline in Patients with Anti-aminoacyl-tRNA Synthetase Antibody-Positive Polymyositis/Dermatomyositis

39. Pyoderma gangrenosum, acne, and unclassified inflammatory bowel disease syndrome: A case report on a new subtype of pyogenic arthritis, pyoderma gangrenosum, and acne syndrome

40. The Characteristic of Transbronchial Lung Cryobiopsy in the Pathological Diagnosis of Hypersensitivity Pneumonitis

43. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease

47. Supplementary Figure S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

48. Table S1 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

49. Figure S6 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

50. Supplementary Table S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Catalog

Books, media, physical & digital resources